强生推出3个新研究平台，指导全球新药研发

2015年2月13日讯/生物谷BIOON/--近日，强生（JNJ）旗下杨森研发（JanssenResearch&Development，JRD）宣布推出3个新的研究平台，专注于疾病预防、疾病拦截和微生物组，推动科技创新，并以变革性的医疗创新，重新定义医疗保健。强生表示，新的团队将与旗下杨森五大治疗领域（心血管和代谢性疾病、免疫学、传染病和疫苗、神经科学、肿瘤学）及外部合作伙伴紧密合作，以支持正在开展的科学研究，推进这些极具潜力的领域中的科学知识，改变当前疾病的管理方式。
——杨森预防中心（JanssenPreventionCenter，JPC），将专注于慢性非传染性疾病（NCDs）的预防，如阿尔茨海默氏症、心脏疾病、癌症和自身免疫性疾病；随着人口老龄化，这些疾病正对全球医疗系统带来日益沉重的负担。JPC总部位于荷兰，并在荷兰（莱顿）、美国（拉荷亚）、英国（伦敦）设有实验室，JPC将充分利用强生旗下Crucell疫苗研究所拥有的世界一流的疫苗发现专业知识和能力，最终目标是确定和研究创新的解决方案，延长人类的健康寿命并降低发病率。
——疾病拦截加速器（DiseaseInterceptionAccelerator，DIA），是一个新的类似孵化器的组织，总部位于美国（拉里坦），该机构将专注于疾病的根本病因。与当前临床公认的诊断时间点相比，DIA将专注于更早的阶段，并寻求解决方案以终止、逆转或抑制疾病的恶化，如1型糖尿病和各类癌症。通过这种新方法，DIA的目的是在个体生病之前预测和预先制止疾病进展。DIA的工作是了解疾病的易感性、风险评估和应对疾病的起源，如遗传因素、环境暴露和表型变化。DIA将结合传统医药及非药物方法，来拦截高危人群的疾病进展，从而改善个体和社会的健康和福利。
——杨森人类微生物组研究所（JanssenHumanMicrobiomeInstitute，JHMI），将专注于一个新兴领域的科学——微生物组（microbiome），越来越多的研究证实，微生物组在人类健康中发挥着至关重要的作用。通过更好地了解微生物组，期望获得针对微生物组在疾病发生中重要作用的更深层次了解，并寻找新的治疗方法，以解决主要自身免疫性疾病和其他目前无充分治疗选择的疾病。通过尖端研究和全球协作网络，JHMI的目标是将微生物组科学转化为变革人类健康的治疗靶标和诊断能力。JHMI将通过美国（剑桥）和欧洲（贝尔泽，比利时）的研究中心促进外部合作。
当前，在全球大部分地区，人们的寿命比以往任何时候更长，但这同时也意味着个体更有可能数年甚至数十年处于健康欠佳的生活之中。因此，针对老龄及生活方式相关疾病的预防策略，存在着巨大的个人和社会经济需求。作为全球领先的医疗保健公司，强生表示，有责任推动医疗创新，实质性改变患者生活质量，并确保医疗系统的长期可持续性。
英文原文：J&JsR&Dgroupcrafts3newplatformstoguideglobaldrugdevelopment
J&Jhascraftedthreenewresearchplatformsdesignedtohelpitsteamsofinvestigatorsfocusonasetofkeystrategicdiseaseinitiativesthatwillhelpguidetheirmultibillion-dollardrugdevelopmentprogram.AndJ&J—whichisaddinganinstituteformicrobiomeR&DalongwithapioneeringefforttopreventType1diabetesintheramp-up-planstousetheircentralpositionintheresearchstructuretohelpcoordinatein-houseworkwiththeirgrowingcastofdevelopmentpartnersaroundtheworld.
Raritan,NJ-basedJanssenResearch&Developmentisntchangingitsfocuson5corediseasefields.Butthepharmagianthasbeenrethinkinghowtobestgoaboutcoordinatingandimprovingabroadpipelineeffort,nowoneofthetopthreepharmaoperationsworldwidewhichconsumesabout$8billionincostseveryyear.Tothatend,thesenewplatformswillconcentrateondiseaseprevention,diseaseinterceptionandthefast-growingmicrobiomefield.
Thisisallaboutnext-gendrugdevelopment,saysWilliamN.Hait,theglobalheadofJanssenResearch&Development.By"identifyingandcorrectlyinterpretingtheearliestsignalsofdiseasesusceptibility,preventingorinterceptingdiseasebeforeitevenbegins,andusingthelatestscientificinsightsfrompromising,emergingfieldslikethemicrobiome,"J&Jcantransformmedicine.
"Thethreeprogramsarepartofanoverallstrategy,whichwerefertoas"Janssen2020,"HaittellsFierceBiotechinanemail."ThethirdpillarofJanssen2020is"ExploreNewSpaces,"ofwhichdiseaseinterceptionispart.The"visionthing"isthatifwearesuccessfulwiththisapproach,inthefuturetherewillnotbepatientsaswethinkofpeoplewithdiseasetoday.Rather,wewillhaveprevented,blocked/interceptedaprocessthatifleftuncheckedwouldhaveledtoillness.Theinterestinmicrobiomealsostemsfromadesiretounderstandthefactorsthatmaintaingoodhealth."
J&Jhasbeenaprolificdealmakeraroundtheglobe.R&DchiefPaulStoffelssetupfourkeydealhubsinLondon,Boston,SanFranciscoandShanghaitocoordinatetheirpartneringworkworldwide.Thesenewplatformsareawayforthecompanytothinkcoherentlyabouthowallitsresearchworkfitstogether,providingaclearsetofguidingprincipleswhileadvancingthescienceneededtomakesurethatthedrugsJ&Jisdevelopingtodayareaclearadvanceforpatients-capableofwinningreimbursement-ifandwhentheybecomeapprovedtherapeuticsdowntheroad.
IndiseasepreventionJ&Jplanstoconcentrateitsworkonsomehugetargets:Alzheimers,heartdisease,cancerandautoimmunediseases,amongothers.Thegoalwillbetospawnnewtherapiesaimedbroadlyatimprovinglongevity,andtheyllbeabsorbingtheexpertiseoftheCrucellVaccineInstitute,whichwascreatedfollowingthe2011Crucellbuyout.
ThefirstgoalforthecompanysdiseaseinterceptionplatformwillbetodevelopnewdiagnosticsandtherapeuticsthatcanidentifyType1diabetesearlyandthenstopitfromprogressing.
"Diseaseinterception(whichisdescribedasanincubator-likeeffort)willinterveneearlierthantodaysclinicallyacceptedpointofdiagnosisandseeksolutionsthatstop,reverseorinhibitprogressiontothatdisease,forinstancetype1diabetesorvariousformsofcancer,"explainedBenjaminWiegand,Ph.D.,GlobalHead,DiseaseInterceptionAccelerator."Throughthisnovelapproach,weaimtopredictandpre-emptanindividualfromprogressingtodisease–beforetheygetsick."Genetics,environmentalfactorsandphenotypicalterationswillbestudiedtohelpguideresearchwork.
J&Jsnewmicrobiomeinstitutewillhelpcoordinatecollaborationsinoneofthehottestfieldsinbiotech,whichiscenteredontheroleteemingpopulationsofbacteriaplayindisease."Throughcutting-edgeresearchandaglobalcollaborativenetwork,weaimtotranslatethescienceofthemicrobiomeintotherapeutictargetsanddiagnosticcapabilitiesthathavethepotentialtotransformhumanhealth,"notedDirkGevers,whoisheadingitup.Theinstitute,thecompanyadds,aimsatfosteringexternalcollaborationsthroughitsanchorresearchcentersinCambridge,MAandinBeerse,Belgium.
"ThePreventionCenterderivesfromtheformerCrucellVaccineInstituteinLeidenanddoesnotrequirere-locating,"addsHait."SomereorganizationoccurredtomovevaccinesforcommunicablediseasesintoourInfectiousDiseasesandVaccinesTherapeuticArea.WeenvisionthattheJanssenHumanMicrobiomeInstitutewillhavetwolocations;amajorlaboratoryeffortinBelgiumonourBeerseCampusandasecondlocationinCambridgeMassachusettsnearourInnovationCenter.Thesenewinitiativeswillbecreatingnewpartnershipsintherelevantscientificareas."
BigpharmahasamixedrecordinR&D.Thetop10companiesspendabout$70billionayeartryingtodevelopnewproducts.AndseveralofthemhaveseeneffortstoclarifyandrevivedrugR&Dflopbadly.GlaxoSmithKlineisnowreorganizingR&Dforthesecondtimein6years.SanofiisdownsizingcancerR&DthisweektoreflectthefailureofoneofChrisViehbacherskeyinitiatives.AndbigcompanieslikeEliLillyflounderedforyears,withsomecriticsstillwonderingifthecompanycangetitsacttogetherandproducegame-changingdrugs.J&Jhasalongwaytogobeforeitcandeterminehowthisnewstrategyworks.Butitistryingsomethingnew.
医药网新闻